ORIGINAL ARTICLE
Role of vascular endothelial growth factor in inducing production of angiopoetin-1 – in vivo study in Fisher rats
Submission date: 2017-04-17
Acceptance date: 2017-07-08
Publication date: 2018-03-06
Pol J Pathol 2017;68(4):326-329
KEYWORDS
TOPICS
ABSTRACT
The aim of the study was to investigate how an intramuscular injection of plasmids with genes coding various pro-angiogenic factors: angiopoetin-1 (ANGPT1), vascular endothelial growth factor (VEGF165) and hepatic growth factor (HGF), influences the production of ANGPT1.
40 Healthy Fisher rats received i.m. injections containing plasmids encoding pro-angiogenic genes in thigh muscles. They were divided into four equal groups. The first group received the plANGPT1 plasmid and the second group- the pIRES/ANGPT1/VEGF165 bicistronic plasmid. The pIRES/VEGF165/HGF bicistronic plasmid was administered to the third group and an empty plasmid (control group) to the fourth group. The animals were euthanized after 12 weeks. In each group, the number of vessels stained with the anti-ANGPT1 antibody was assessed under an optical microscope. The anti-ANGPT1 antibodies stained the vessels in all the groups. There were on average 14.1 ±2.3 vessels in the the plANGPT1 group, 32.5 ±10.5 in the pl/RESANGPT1/VEGF group and 30.8 ±13.3 in the plRES/HGV/VEGF group. There were on average 7.3 ±2.3 stained vessels (p < 0.0001) in the control group . The VEGF plays a role in the induction of the production of ANGPT1. The administration of plasmids only encoding ANGPT1 does not induce its production.
40 Healthy Fisher rats received i.m. injections containing plasmids encoding pro-angiogenic genes in thigh muscles. They were divided into four equal groups. The first group received the plANGPT1 plasmid and the second group- the pIRES/ANGPT1/VEGF165 bicistronic plasmid. The pIRES/VEGF165/HGF bicistronic plasmid was administered to the third group and an empty plasmid (control group) to the fourth group. The animals were euthanized after 12 weeks. In each group, the number of vessels stained with the anti-ANGPT1 antibody was assessed under an optical microscope. The anti-ANGPT1 antibodies stained the vessels in all the groups. There were on average 14.1 ±2.3 vessels in the the plANGPT1 group, 32.5 ±10.5 in the pl/RESANGPT1/VEGF group and 30.8 ±13.3 in the plRES/HGV/VEGF group. There were on average 7.3 ±2.3 stained vessels (p < 0.0001) in the control group . The VEGF plays a role in the induction of the production of ANGPT1. The administration of plasmids only encoding ANGPT1 does not induce its production.
REFERENCES (25)
1.
Iida O, Nakamura M, Yamauchi Y, et al. Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: Olive registry, a prospective, multicenter study in japan with 12-month follow-up. Circ Cardiovasc Interv 2013; 6: 68-76.
2.
Rowlands TE, Donnelly R. Medical therapy for intermittent claudication. Eur J Vasc Endovasc Surg 2007; 34: 314-321.
3.
Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377: 1929-1937.
4.
Hee Ko S, Bandyk DF. Therapeutic angiogenesis for critical limb ischemia. Semin Vasc Surg 2014; 27: 23-31.
5.
Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease, part I: angiogenic cytokines. Circulation 2004; 109: 2487-2491.
6.
Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease, part II: cell-based therapies. Circulation 2004; 109: 2692-2697.
7.
Skóra J, Barć P, Dawiskiba T, et al Angiogenesis after plasmid VEGF165 gene transfer in animals model. Centr Eur J Immunol 2013; 38: 305-309.
8.
Sadakierska-Chudy A, Skóra J, Barć P, et al. Angiogenic therapy for clinical lower limb ischemia. Adv Clin Exp Med 2010; 19: 347-359.
9.
Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009; 105: 724-736.
10.
Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003; 114: 85-92.
11.
Suri Ch, McClain J, Thurston G, et al. Increased Vascularization in Mice Overexpressing Angiopoietin-1. Science 1998; 282: 468-471.
12.
Gamble JR, Drew J, Trezise L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000; 87:603-607.
13.
Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-1169.
14.
Rubin JS, Chan AM, Bottaro DP, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A 1991; 88: 415-419.
15.
Kan M, Zhang GH, Zarnegar R, et al. Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE. Biochem Biophys Res Commun 1991; 174: 331-337.
16.
Barc P, Plonek T, Baczynska D, et al. A combination of VEGF165/HGF genes is more effective in blood vessels formation than ANGPT1/VEGF165 genes in an in vivo rat model. Int J Clin Exp Med 2016; 9: 12737-12744.
17.
Sengupta S, Gherardi E, Sellers LA, et al. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2003; 23: 69-75.
18.
Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026.
19.
Shimamura M, Sato N, Oshima K, et al. Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 2004; 109: 424-431.
20.
Min JK, Lee YM, Kim JH, et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 2005; 96: 300-307.
21.
Jadczyk T, A Faulkner A, Madeddu P. Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology. Br J Pharmacol 2013; 169: 247-268.
22.
Suzuki H, Iso Y. Clinical Application of Vascular Regenerative Therapy for Peripheral Artery Disease. Biomed Res Int 2013; 2013: 179730.
23.
Kim I, Moon SO, Park SK, et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001; 89: 477-479.
24.
Chae JK, Kim I, Lim ST, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 2000; 20: 2573-2578.
25.
Skóra J, Biegus J, Pupka A, et al. Molecular basics of angiogenesis. Postepy Hig Med Dosw 2006; 60: 410-415.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
